The FirstTake Podcast – Does 2022 promise a bumper year in pharma M&A?

Update: 2021-12-17

Description

FirstWord Pharma PLUS editors Michael Flanagan, Virginia Li and Simon King discuss whether a spate of deals this week is evidence of an eventful year ahead for bio-pharma M&A, take a closer look at Pfizer’s acquisition of Arena Pharmaceuticals and highlight some of the standout moments from the recent ASH conference.

Comments

In Channel

The FirstTake Podcast – NK Cell therapy, CAR-T in solid tumours and our early take on Q1 earnings season

2022-04-2812:49

The FirstTake Podcast – Previewing AACR

2022-04-0411:12

The FirstTake Podcast – The FDA faces up to a tricky ALS regulatory decision, Roche’s TIGIT setback and more…

2022-03-3116:38

The FirstTake Podcast – A landmark cancer approval, Pfizer’s Arena deal delivers and the expert view on recent breast cancer developments

2022-03-2412:55

The FirstTake Podcast – Sanofi’s breast cancer hopeful fails to deliver

2022-03-1714:50

The FirstTake Podcast – Gilead’s oncology strategy under the spotlight

2022-03-1015:40

The FirstTake Podcast – Where next for gene editing?

2022-03-0311:39

The FirstTake Podcast – Does a paradigm shift in breast cancer beckon?

2022-02-2412:24

The FirstTake Podcast – More questions than answers for Sage and Biogen

2022-02-1712:28

The FirstTake Podcast – AdCom upset for Lilly and Innovent

2022-02-1013:54

The FirstTake Podcast – More Aduhelm fallout and JP Morgan wraps for another year